IMPACT OF LONG-TERM TREATMENT WITH CONTINUOUS TENOFOVIR ALAFENAMIDE (TAF) OR AFTER SWITCH FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)

This article has no abstract
Epistemonikos ID: c3d5bb2c3780e5cc5bd00bc655127b7c01293558
First added on: Apr 30, 2026